文献速递认知障碍与谵妄

成人低活动型谵妄的药物治疗:文献简要报告

Pharmacologic Treatment for Hypoactive Delirium in Adult Patients: A Brief Report of the Literature.
PubMed 文献 · J Am Med Dir Assoc · 2021-02-05

该报告系统检索PubMed和Web of Science至2020年9月20日,评估成人及老年患者低活动型谵妄的药物治疗研究。52篇相关文献中仅4篇符合标准,涉及氟哌啶醇、齐拉西酮、阿立哌唑和哌甲酯。阿立哌唑显示低活动型谵妄完全缓解(P < .001),哌甲酯显示认知功能显著改善(P < .001),齐拉西酮和氟哌啶醇与安慰剂无显著差异。

要点

  • 低活动型谵妄药物治疗的临床研究数量有限,仅4篇符合纳入标准。
  • 阿立哌唑与低活动型谵妄完全缓解相关(P < .001)。
  • 哌甲酯与认知功能显著改善相关(P < .001)。

核心结论

  • 针对低活动型谵妄的药物治疗临床研究有限,阿立哌唑和哌甲酯显示出有希望的结果。

研究设计与样本

  • 系统检索PubMed和Web of Science自建库至2020年9月20日的文献,纳入评估成人(≥18岁)及老年患者低活动型谵妄药物治疗的研究。
  • 52篇相关文献中仅4篇(8%)符合选择标准,包括2项队列研究和2项随机对照试验,后因数据重复排除1篇报告。
  • 研究质量采用英国国家卫生与临床优化研究所(NICE)的队列研究和随机对照试验指南评估。

主要发现

  • 纳入研究涉及4种药物:氟哌啶醇、齐拉西酮、阿立哌唑和哌甲酯。
  • 阿立哌唑显示低活动型谵妄完全缓解(P < .001)。
  • 哌甲酯显示认知功能显著改善(P < .001)。
  • 齐拉西酮和氟哌啶醇与安慰剂相比无显著差异。

关键数值与推荐

  • 阿立哌唑与低活动型谵妄完全缓解相关(P < .001)。
  • 哌甲酯与认知功能显著改善相关(P < .001)。
  • 齐拉西酮和氟哌啶醇与安慰剂比较无显著差异。

临床怎么用

  • 对于低活动型谵妄患者,阿立哌唑和哌甲酯可能是有希望的治疗选择,但需结合有限证据个体化决策。

局限性

  • 符合纳入标准的临床研究数量有限(仅4篇),证据基础薄弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this report was to identify medications that can be used to treat hypoactive delirium. DESIGN: A systematic search of PubMed and Web of Science from inception through September 20, 2020. SETTING AND PARTICIPANTS: Reports evaluating different pharmacologic treatments for hypoactive delirium in adults (age 18 years and older) and geriatric patients were included. METHODS: Three independent investigators reviewed the abstracts, using the Rayyan QCRI review tool to decide which articles were eligible for inclusion. Hereafter, articles were read completely for final inclusion. Study quality was assessed using the guidelines from the National Institute for Health and Care Excellence for cohort studies and randomized control trials. RESULTS: Of the 52 relevant articles, only 4 (8%) met the selection criteria. Two were cohort studies whereas the other 2 were randomized control trials. After further review, one of the reports was excluded because the same data were used as in one of the randomized control trials. In total, 4 different pharmacologic therapies were used in the selected studies: haloperidol, ziprasidone, aripiprazole, and methylphenidate. Aripiprazole showed a complete resolution of hypoactive delirium (P < .001), and methylphenidate showed a significant amelioration in cognitive function (P < .001). Ziprasidone and haloperidol did not show significant differences compared with placebo. CONCLUSIONS AND IMPLICATIONS: A limited number of clinical studies on the treatment of hypoactive delirium are available. Aripiprazole and methylphenidate showed promising results in the treatment of hypoactive delirium.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Lodewijckx E, Debain A, Lieten S, et al. Pharmacologic Treatment for Hypoactive Delirium in Adult Patients: A Brief Report of the Literature. J Am Med Dir Assoc. 2021. PMID: 33549562. doi:10.1016/j.jamda.2020.12.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。